Detection of early prostate cancer using a hepsin-targeted imaging agent.

Early detection and diagnosis of prostate cancer is key to designing effective treatment strategies. Microarrays have resulted in the discovery of hepsin (HPN) as a biomarker for detection of prostate cancer. In this study, we explore the development of HPN imaging probes for detection of prostate cancer. We used phage display to isolate HPN binding peptides with 190 + 2.2 nmol/L affinity in monomeric form and high specificity. The identified peptides were able to detect human prostate cancer on tissue microarrays and in cell-based assays. HPN-targeted imaging agents were synthesized by conjugating multiple peptides to fluorescent nanoparticles to further improve avidity through multivalency and to improve pharmacokinetics. When injected into mouse xenograft models, HPN-targeted nanoparticles bound specifically to HPN-expressing LNCaP xenografts compared with non-HPN-expressing PC3 xenografts. HPN imaging may provide a new method for detection of prostate cancer.

[1]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.

[2]  David A Jones,et al.  Isolation of a colon tumor specific binding peptide using phage display selection. , 2003, Neoplasia.

[3]  Ralph Weissleder,et al.  In vivo imaging of molecularly targeted phage. , 2006, Neoplasia.

[4]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[5]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[6]  S. Woolf.  Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.

[7]  S. Loening,et al.  The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? , 2004, The Journal of urology.

[8]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[9]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[10]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[11]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[12]  V. Srikantan,et al.  HEPSIN inhibits cell growth/invasion in prostate cancer cells. , 2002, Cancer research.

[13]  Vasilis Ntziachristos,et al.  Tomographic fluorescence imaging of tumor vascular volume in mice. , 2007, Radiology.

[14]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[15]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[17]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[18]  V. Vasioukhin.  Hepsin Paradox Reveals Unexpected Complexity of Metastatic Process , 2004, Cell cycle.

[19]  P. Nelson.  Identifying Immunotherapeutic Targets for Prostate Carcinoma through the Analysis of Gene Expression Profiles , 2002, Annals of the New York Academy of Sciences.

[20]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[21]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[22]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[23]  Ralph Weissleder,et al.  Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle , 2005, Circulation research.

[24]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[25]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[26]  K. Shigemasa,et al.  Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. , 1997, Cancer research.

[27]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[28]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[29]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.